A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Protocol No
NGM-18-0402
Principal Investigator
Ben George
Phase
I
Summary
The purpose of this study is to find out what effects, both good and/or bad, of the study drug “NGM120”, as well as the combination of NGM120 and standard therapy (gemcitabine and Abraxane) may have on you and your type of cancer and your cancer associated loss of appetite, weight loss and loss of muscle.
Description
NGM120, given as an injection, is designed to block a factor that is associated with cancer. NGM120 has shown in various animal models of cancer to reduce tumor size and improve symptoms of cancer.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: